Product image of Ibandronsäure Beta (Ibandronic Acid) supplied by GNH India

Ibandronsäure Beta

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronsäure Beta (Ibandronic Acid)

Ibandronic Acid, the active ingredient in Ibandronsäure Beta, is a bisphosphonate presented as an injectable solution for intravenous administration. It is indicated for the treatment of postmenopausal osteoporosis and for managing Paget's disease of bone, helping to reduce bone turnover and strengthen skeletal integrity in affected patients.

GNH India supplies Ibandronsäure Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for intravenous bisphosphonate therapy across global markets and research institutions with consistent quality control and regulatory compliance.

Manufacturer / TM Owner

Betapharm Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibandronsäure Beta belongs to the bisphosphonate class and is used to treat conditions characterized by excessive bone resorption.

  • Postmenopausal osteoporosis: improves bone mineral density and lowers the risk of vertebral and non‑vertebral fractures.
  • Paget's disease of bone: normalises abnormal bone remodeling and reduces associated pain.
  • Osteoporosis (including male patients): increases bone strength and helps prevent fractures in individuals with low bone mass.

How It Works

  • Ibandronic Acid binds selectively to hydroxyapatite crystals on bone surfaces, especially at sites of active remodeling. When osteoclasts attach to the drug‑coated bone, the compound is internalised, disrupting the mevalonate pathway, inducing osteoclast apoptosis and thereby inhibiting bone resorption.

Side Effects

Ibandronsäure Beta may cause a range of adverse reactions.

Common Side Effects

  • Acute‑phase reaction: fever, myalgia, and flu‑like symptoms.
  • Nausea or mild gastrointestinal discomfort.
  • Headache or dizziness.
  • Injection‑site pain or erythema.
  • Transient hypocalcaemia.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw, especially after dental procedures.
  • Atypical femur fractures with prolonged use.
  • Severe renal impairment or acute kidney injury.
  • Anaphylactic or severe hypersensitivity reactions.
  • Atrial fibrillation or cardiac arrhythmias reported in rare cases.

Precautions & Warnings

Before using Ibandronsäure Beta, consider the following precautions.

  • Renal function: assess glomerular filtration rate and avoid use in severe renal impairment.
  • Calcium and vitamin D status: ensure adequate supplementation to prevent hypocalcaemia.
  • Hypocalcaemia: correct any low serum calcium levels prior to infusion.
  • Pregnancy and lactation: avoid unless the potential benefit justifies the potential risk.
  • Drug interactions: review concomitant medications for possible renal or calcium‑related effects.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ibandronsäure Beta can interact with several medicines.

Major Interactions (Avoid)

  • Concurrent use of other bisphosphonates: may increase toxicity risk.
  • Co‑administration with nephrotoxic agents (e.g., aminoglycosides, NSAIDs): heightened renal adverse events.
  • Calcium, magnesium, iron, or zinc supplements taken within 2 hours of infusion: markedly reduced drug absorption.

Moderate Interactions (Monitor Closely)

  • NSAIDs: monitor renal function and blood pressure.
  • Systemic corticosteroids: may exacerbate bone loss if not supplemented.
  • Vitamin D analogues: watch for hypercalcaemia.
  • Anticoagulants: observe for potential bleeding changes.
  • Diuretics: assess electrolyte balance, especially calcium.

Frequently Asked Questions

Ibandronsäure Beta contains Ibandronic Acid, a bisphosphonate indicated for the treatment of postmenopausal osteoporosis and for managing Paget's disease of bone. It works by reducing excessive bone turnover, thereby strengthening the skeleton and lowering fracture risk in these conditions.

Ibandronic Acid binds to hydroxyapatite at sites of active bone remodeling. When osteoclasts attach to the drug‑coated bone, the compound is taken up, disrupting the mevalonate pathway, triggering osteoclast apoptosis and consequently inhibiting bone resorption.

The specific dose and infusion schedule are determined by the prescribing clinician based on the patient’s condition, renal function and overall treatment plan. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed.

Safety data for Ibandronsäure Beta during pregnancy and lactation are limited. It is generally avoided unless the potential therapeutic benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Ibandronsäure Beta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Ibandronsäure Beta is an intravenous bisphosphonate, offering rapid and complete bioavailability compared with oral agents such as alendronate or risedronate, which have variable absorption. Intravenous delivery avoids gastrointestinal irritation but requires clinical setting for infusion and careful renal monitoring.

The product must be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original packaging until use to maintain stability and potency.

Ibandronsäure Beta is given as an intravenous infusion, typically over a short period (often 15–30 minutes) in a clinical setting. The infusion is performed by qualified healthcare personnel following aseptic technique and monitoring for acute‑phase reactions.

Serious adverse events include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and rare hypersensitivity reactions such as anaphylaxis. Patients should be monitored for these conditions, especially during prolonged therapy.

Ibandronsäure Beta is contraindicated in patients with severe renal impairment (e.g., creatinine clearance <30 mL/min), known hypersensitivity to ibandronate or any formulation components, and those with active dental or jaw infections. Caution is also advised for individuals with hypocalcaemia or uncontrolled metabolic bone disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT